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Background: Posterior capsule opaciﬁ  cation is one of the most frequent adverse events 
following cataract surgery. This manuscript reports the lifetime cost of complications linked to 
posterior capsule opaciﬁ  cation using three types of intraocular lens with square edges.
Methods: Costs were estimated from a retrospective study of patients who underwent cataract 
surgery and data from the literature. The lenses studied were hydrophobic acrylic (SA60AT and 
AR40E) and hydrophilic acrylic (XL-Stabi) lenses with square edges. The frequency of Nd-Yag 
laser capsulotomies after 4 years’ survival was estimated by two methods: the ﬁ  rst involved 
linear adjustment of the rate at 5 and 6 years follow-up and then application of a constant rate 
after 6 years; the second involved linear adjustment after 5 years follow-up. The economic 
perspective was that of the French Sickness Fund.
Results: After 3 years’ follow-up the percentage of patients who had not undergone laser 
Nd-Yag capsulotomy was 86.9% with SA60AT, 76.6% with AR40E and 54.6% with XL-Stabi 
lenses (p  0.001). The total cost of capsulotomy and management of complications per patient 
lifetime was estimated to be  90.5 for SA60AT,  189.5 for AR40E and  288.0 for XL-Stabi 
lenses by the ﬁ  rst extrapolation method. With the second method of extrapolation the costs were 
94.8,  200.0 and  300.2, respectively.
Interpretation: Lower costs for cataract surgery and management of related complications 
were observed with the two hydrophobic acrylic lenses; the lowest costs were observed with 
SA60AT lenses as they were associated with fewer Nd-Yag laser capsulotomies.
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Introduction
The most frequent postsurgical complication of cataract surgery is posterior capsule 
opaciﬁ  cation (PCO),1 which affects at least 20% of patients 3 years after surgery and 
around 38% 9 years after.2 When PCO becomes severe and affects the visual acuity 
of the patient, treatment by laser neodymium-Yag (Nd-Yag) is carried out.3
Secondary effects of laser-Yag capsulotomies are generally rare and transient, 
except for the formation of Elschnig pearls and elevation of intraocular pressure 
(IOP). The increase in IOP affects 4% to 7% of patients, particularly those with ocular 
comorbidities such as glaucoma, strong myopia or aphakia.4–5 Kato et al6 observed an 
increased rate of formation of Elschnig pearls after capsulotomy in 47.6% of the eyes, 
12 months after capsulotomy. Formation of these pearls required a second operation 
in approximately 1/3 of eyes affected. According to Kurosaka,7 69.2% of the eyes 
developed Elschnig pearls during the 32.1 months post laser Nd-Yag follow-up.
The other secondary effects of cataract surgery generally affect less than 3% of 
patients. Rollin et al8 observed several cases of transient ocular hypertension and 
uveitis, and a single case of cystoid macular edema (CMO) after Nd-Yag laser. Boschi 
et al9 reported an incidence of CMO of 3.1%, an elevation of IOP in 11.9% and altera-
tion of the lens in 27%.Clinical Ophthalmology 2009:3 278
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Retinal damage after capsulotomy is a rare event. According 
to Javitt et al10 the risk of retinal detachment was 3.9 times 
higher (CI 95%: 2.89−5.25) in patients who had capsulotomy. 
The risk of retinal tearing was 2.24 times higher in patients 
who had capsulotomy.
In a recent study, Billotte and Berdeaux developed a Markov 
model to evaluate the frequency of complications following 
capsulotomy using data from the literature.11 If the intra-
ocular lens (IOL) is replaced to reduce the frequency of laser 
Nd-Yag capsulotomies from 10% to 2.5%, 1201 detachments 
of the retina, 1201 CMO, 1342 cases of glaucoma and 5882 
increases in IOP per year would be avoided per 400,000 subjects 
undergoing cataract surgery per year during the 3 years post 
surgery.
The costs linked to cataract surgery include insertion of 
the IOL but also costs linked to management of complica-
tions, including the cost of capsulotomies and related second-
ary effects. The frequency of capsulotomy depends mainly 
on the type of lens inserted. This analysis compared the costs 
over the lifetime of the patient after cataract surgery using 
three types of lens with square edges.
Materials
This economic analysis was performed from the perspective 
of the French Sickness Fund. It was based on the results 
of a retrospective analysis of patients picked up at random 
implanted with square edge IOLs. These clinical results were 
extrapolated to the entire life of the cohorts to allow calcula-
tion of the lifetime costs for the population.
Study plan
This retrospective, multicentric study was carried out in 
France by 10 ophthalmology centers. IOLs studied all 
had square edges: AcrySof® SA60AT (Alcon), AR40E 
(Advanced Medical Optics) and XL-Stabi (Zeiss-Ioltech). 
SA60AT and AR40E are hydrophobic acrylic lenses and 
XL-Stabi is a hydrophilic acrylic lens. The results of the 
multicentric retrospective study have been described in a 
previous publication.12 767 eyes treated with SA60AT (n 
= 250), AR40E (n = 254), or XL-Stabi (n = 263) were ana-
lyzed. After 3 years’ follow-up the proportions of patients 
who had not received Nd-Yag laser treatment were 86.9% 
with SA60AT, 76.6% with AR40E, and 54.6% with XL-
Stabi (p  0.001). Cox’s model adjusted for center effects 
and the presence of diabetes estimated risk ratios of 2.8 for 
AR40E (p  0.0005) and 5.1 for XL-Stabi (p  0.0001), 
compared to the reference lens SA60AT.
Evaluation of the rate of laser Nd-Yag 
capsulotomies and data extrapolation
The survival curves resulting from the retrospective study 
provided a rate of capsulotomy during 4 years of follow-up. 
After this 4-year follow-up period, two extrapolation methods 
were used to evaluate the frequency of Yag:
1.  Linear extrapolation of the survival curves from 5 years to 
26 years of follow-up (that is, until the age of 100 years; 
patients had a mean age of 74 years at the time of surgical 
intervention in the retrospective study). The rate of Yag 
was calculated according to the following method:
  For the ﬁ  rst 4 years of follow-up: Rate of Yag at y years of 
follow-up = cumulative rate of Yag at y years – cumulative 
rate of Yag at (y−1) years.
  For the years 5 to 26 of follow-up: Rate of Yag at y years 
of follow-up = rate of Yag at (y–1) years/2.
  It was necessary to divide the rate of Yag by two to ﬁ  t 
with long term cohort follow-up curves.11
2.  Extrapolation of the survival curves from 5 to 6 years 
of follow-up, with a constant rate of laser Nd-Yag from 
then on. Indeed, Billotte et al11 demonstrated that beyond 
6 years of follow-up, the cumulative rate of capsulotomies 
remains constant. The rate of Yag was calculated accord-
ing to the following method:
  For the ﬁ  rst 4 years of follow-up: Rate of Yag at y years of 
follow-up = cumulative rate of Yag at y years – cumulative 
rate of Yag at (y–1) years.
  For the years 5 to 6 of follow-up: Rate of Yag at y years 
of follow-up = rate of Yag at (y–1) years/2.
Finally, a rate of capsulotomy taking into account survival 
was calculated to obtain the rate of Yag in the population 
included at each instant t. This rate was then used in the 
estimation of costs.
Survival rates were obtained from the INSEE data of 
January 1st 2005 (http://www.insee.fr).
Consumption of care
Only health care consumption associated with Nd-Yag laser 
and its complications was estimated, since the cost of cataract 
surgery itself was similar for the three lenses. It was estimated 
by the centers that participated in the retrospective European 
study, for each type of complication identiﬁ  ed in a review 
of the literature.17
Direct unit costs
Cost were expressed in Euro, 2006 (€1 = US$1.35). Two 
discount rates were used: 0% and 5%.Clinical Ophthalmology 2009:3 279
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The costs of treatment and their level of reimbursement 
were obtained directly from the Dictionnaire Vidal 2006.13 
The costs were reimbursed at 65% by the Sickness Fund.
The costs of medical examination and consultations 
were obtained from the Classiﬁ  cation Commune des Actes 
Médicaux (CCAM) and the Nomenclature Générale des 
Actes Professionnels (NGAP) 2005 (http://www.insee.fr). 
These were reimbursed at 70% by the Sickness Fund, with 
an inclusive fee of €1 for the patient for consultations.
The costs of hospitalization were obtained the “Programme 
Médicalisé des Systèmes d’Information” (PMSI) (http://
www.insee.fr). The most relevant Diagnosis Related Group 
(DRG) was chosen using the diagnostic classiﬁ  cation of the 
International Classiﬁ  cation of Diseases (ICD).
Indirect unit costs
The low vision and blindness incidence rates following glau-
coma or high intraocular hypertension were estimated from 
the literature. According to Coffey et al14 the prevalence of 
blindness was 7.3% among glaucoma patients and 14.6% for 
low vision. Chen et al15 estimated at 15 years that cumulative 
incidence rate for low vision was 14.6% and 6.4% for blind-
ness. Hattenhauser et al16 found very similar estimates: 27% 
(low vision) and 9% (blindness), at 20 years. We applied an 
average yearly incidence rate which was hypothesized to stay 
constant over the time horizon of our model.
Indirect costs are those costs associated with the develop-
ment of blindness. They take into account all the socialized 
costs (converting the accommodation, moving home, help 
with house work, cooking, etc), the loss of revenue due to 
visual handicap, the hourly cost of helpers caring for the blind 
and the social ﬁ  nancial help for the handicap. These costs were 
estimated at  7,242/person/year and  16,679/person/year, for 
low vision and blindness, respectively, in France.17
Evaluation of costs per complication
The costs for transient complications were estimated using 
the following formula:
Cost/year of follow-up for a given complication = (ﬁ  nal 
rate of Yag) × (% complication) × (cost of complication).
For permanent complications (glaucoma and persistent 
elevation of IOP), we multiplied the annual cost per life 
expectancy taking into account patient gender:
Cost/year of life of follow-up for a given complication = (rate 
of Yag) × (% complication) × (annual cost of complication) × 
(life expectancy in years).
A model of budget impact for the Sickness Fund was 
also designed to calculate costs using the hypothesis that 
all lens implantations were carried out with one of the 
three lenses.
Results
Rate of laser Nd-Yag
Figure 1 shows the calculated rate of patients not undergoing 
laser Nd-Yag capsulotomy for each of the three IOL using the 
two described extrapolation methods. The lowest rate was 
observed with the hydrophilic acrylic lens, XL-Stabi, with 
54.6% of patients not affected at 3 years of follow-up.
Rate of post-laser Nd-Yag complications 
and health care consumption
Only the most frequent or most serious complications were 
considered in this analysis:
•  Transient increase in IOP: according to published studies, 
the frequency of IOP increase greater than 10 mmHg 
after capsulotomy ranges from 4.1% to 6.8%.18–21. For 
the evaluation of costs, an average rate of 5% was used. 
In 1% of cases this increase is persistent.22
•  The appearance of glaucoma: the incidence varies from 
0.2% to 6.7% according to different studies, with a 
median of 1.34%.20,21,23,24 The rate considered in this 
study was 1.34%. A rate of 7.3% was used to estimate 
the indirect costs linked to the possibility of becoming 
blind following glaucoma.14
•  CMO: the incidence of CMO varies from 0.55% to 
4.9% according to different studies, with a median of 
1.2%.20,24,25,29–33 The rate considered in this study was 
1.2%.
•  Detachment of the retina: the incidence varies from 0.08% 
to 4.16% according to different studies10,23,26–40 with a 
median of 1.2%. The rate considered here was 1.2%.
•  Decrease in visual acuity: the incidence varies from 1.4% 
to 7%, with a median of 4%.19,20 The rate considered in 
this study was 4%.
•  Formation of Elschnig pearls: approximately 47.6% of 
patients are affected.6 A second capsulotomy is necessary 
to remove these pearls in 18% to 33% of cases,6,7 with 
a mean of 25% of cases.
Table 1 shows the health care consumption for each of 
these complications. These data were obtained by questioning 
the centers that participated in the retrospective European 
study.
Total cost of complications
The cost of cataract surgery was the same for all three lenses 
and was not taken into account in the analysis. In France, Clinical Ophthalmology 2009:3 280
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Figure 1 Annual rates of patients not undergoing Nd-Yag per lens according to two levels of extrapolation.Clinical Ophthalmology 2009:3 281
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the IOL cost is included in the DRG price corresponding to 
the intervention.
A cost per episode was estimated for the transient com-
plications (Table 2).
For the persistent complications, an annual cost was cal-
culated and applied for each year of survival of the patient.
Cost of complications according 
to type of IOL
According to the method of extrapolation used, the highest 
costs were observed for the hydrophilic acrylic lens, XL-Stabi, 
with a cost per patient of  318.74 to  330.71 (Table 3). Out 
of the two hydrophobic acrylic lenses, SA60AT was associ-
ated with the lowest costs of  99.83 to  104.17 depending on 
the extrapolation method compared to €208.15 to €218.38 
for AR40E. A 5% discount rate did not modify the results 
dramatically.
Irrespective of the extrapolation method or type of lens, 
the cost of laser Nd-Yag represents approximately 24% of the 
total cost of cataract surgery complications. The indirect costs 
linked to glaucoma and persistent elevation of IOP leading to 
blindness are also an important part of the total cost as they 
represent approximately 1/3 of the cost overall.
Budget impact model according 
to type of lens
According to the PMSI data for 2005, 529,987 interventions 
for cataracts were carried out. The three types of lens studied 
Table 1 Medical consumption according to the type of side effects
Post-laser Nd-Yag 
side effects
% of patients 
affected
Consultations 
(n)
Treatments Examinations Hospitalizations
Transient increase in IOP 5.00% 2 Timolol + xalatan, 
azopt (50%)
Visual ﬁ  eld + gonoscopy 
(50%)
–
Glaucoma and persistent 
elevation of IOP
Glaucoma: 1.34% 
IOP: 1.00%
2.5 Timolol + xalatan or 
azopt (50%) + betoptic
Visual ﬁ  eld + gonoscopy 
(50%)
Trabeculotomy 
in 24.2% of cases. 
CCAM
Cystoid macular edema 1.20% 3.5 Indocollyre + timolol 
or azopt (50%)
Angiography (50%) –
Detachment of the 
retina 
1.20% 1 – – 02C02V/02C02W 
detachment of the 
retina
Decrease in visual acuity 4.00% 3 Angiography
Elschnig pearls 47.60% 1 Indocollyre + laser 
Nd-Yag in 25% of cases
Abbreviations: CCAM, Classiﬁ  cation Commune des Actes Médicaux; IOP, intraocular pressure; Nd-Yag, neodymium-Yag.
Table 2 Unit costs of laser Nd-Yag and its complications
Post-laser   Yag complications Cost in the 1st year (€) Annual cost in the 
following years (€)
Laser Nd-Yag 98.16 0
Transient increase in intraocular pressure 62.16 0
Persistent increase in intraocular pressure 277.30 277.30
Glaucoma (direct costs) 277.30 277.30
Cost of low vision 7,242 7,242
Cost of blindness 15,679 15,679
Macular edema 108.13 0
Detachment of the retina 3023.54 0
Decrease in visual acuity 96.32 0
Elschnig pearls 36.31 0
Abbreviation: Nd-Yag, neodymium-Yag.Clinical Ophthalmology 2009:3 282
Boureau et al
here represented 64% of the market: 38% for SA60AT, 
12% for AR40E and 14% for XL-Stabi. This therefore 
represents:
•  204,045 interventions with SA60AT
•  63,598 interventions with AR40E
•  74,198 interventions with XL-Stabi,
or a total of 341,842 interventions.
Assuming that all of these 341,842 interventions were 
carried out with the same IOL, we can estimate that the hydro-
philic IOL, XL-Stabi, generated an additional cost of €67.5 to 
€70.2 million (depending on the extrapolation method used) 
as compared to SA60AT (Table 4). Considering the AR40E 
hydrophobic lens, the induced incremental cost as compared 
to SA60AT is lower than that of XL-Stabi. Nevertheless, this 
Table 3 Lifetime cost of post-capsulotomy complications per patient and according to type of lens, according to the method of extrapo-
lation used (€)
SA60AT AR40E XL-Stabi
Linear extrapolation of the rate of   Yag at 5 and 6 years follow-up, and then a constant rate
 Laser  Nd-Yag 21.29 44.92 67.46
  Transient increase in IOP 0.67 1.42 2.14
  Persistent increase in IOP 6.35 13.24 20.26
   Persistent increase in IOP
leading to blindness (indirect costs)
18.09 37.35 58.13
  Glaucoma (direct costs) 8.51 17.74 27.15
   Glaucoma leading to blindness 
(indirect costs)
24.24 50.05 77.90
 Macular  edema 0.28 0.59 0.89
  Detachment of the retina 7.83 16.52 24.80
  Decrease in visual acuity 8.82 18.40 28.15
 Elschnig  pearls 3.75 7.91 11.88
 Direct  costs
 Indirect  costs
 Total
  Total discounted at 5%
57.49
42.34
99.83
81.41
120.74
87.40
208.15
170.37
182.71
136.03
318.74
259.63
Linear extrapolation of the rate of  Yag from 5 to 26 years of follow-up
 Laser  Nd-Yag 22.48 47.85 70.84
  Transient increase in IOP 0.71 1.51 2.24
  Persistent increase in IOP 6.61 13.89 21.01
   Persistent increase in IOP 
leading to blindness (indirect costs)
18.68 38.67 59.69
  Glaucoma (direct costs) 8.86 18.61 28.16
   Glaucoma leading to blindness 
(indirect costs)
25.03 51.82 79.99
 Macular  edema 0.30 0.63 0.94
  Detachment of the retina 8.31 17.69 26.18
  Decrease in visual acuity 9.19 19.29 29.19
 Elschnig  pearls 3.96 8.42 12.47
 Direct  costs
 Indirect  costs
 Total
  Total discounted at 5%
60.46
43.71
104.17
84.78
127.89
90.49
218.38
178.31
191.03
139.68
330.71
268.90
Cost at 5 years
 Direct  costs
 Indirect  costs
 Total
30.79
0.97
31.76
62.52
2.21
64.73
100.17
3.08
103.25
Abbreviation: Nd-Yag, neodymium-Yag; IOP, intraocular pressure.Clinical Ophthalmology 2009:3 283
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additional cost adds up to between  33.9 and  35.9 million 
which has to be borne by Social Insurance.
Discussion
This economic study is principally based on the results 
obtained from a retrospective study whose principal objective 
was to estimate the rate of complications after cataract surgery 
with the insertion of three different IOL with square edges. The 
main complication was PCO and its treatment by laser Nd-Yag. 
This study showed that the lowest rate of capsulotomy was 
obtained with hydrophobic acrylic lenses and the highest rate 
with hydrophilic acrylic lenses. As the three lenses studied all 
had square edges, these results also illustrate the inﬂ  uence of 
material on the occurrence of Nd-Yag treatment independently 
of the geometric form of the edges of the lens.41–43
In a previous European study, we showed that the highest 
cost:efﬁ  cacy ratio was observed with hydrophilic lenses and 
the lowest with hydrophobic lenses, in France, Germany, 
Spain and Italy.44 However, the lenses considered in this 
European study had very variable geometries. It is therefore 
difﬁ  cult to know if the differences in cost estimated were due 
to material and/or the geometry of the lens.
The lenses studied here all had square edges, a geometry 
which is considered to be optimal, and the results demonstrate 
that material nevertheless plays an important role in the rate of 
capsulotomy and therefore on the cost of cataract surgery. The 
rate of PCO was highest with hydrophilic acrylic lenses, and 
the highest costs were also observed with the same lenses.
Generalization to other European countries should be 
performed cautiously since economic regulation might differ. 
However all countries having the following characteristics 
are likely to reproduce the reported results: (1) cost of IOL 
included in the DRG, (2) a fee-for-service payment for cap-
sulotomy, (3) similar resource utilization and unit costs to 
treat capsulotomy adverse events.
The association between capsulotomy and retinal detach-
ment was questioned by Neuhann et al45 in a paper published 
after this model was developed. While no association was 
reported, it is important to note that cost related to retinal 
detachment represented less than 8% of the SA60AT undis-
counted total cost.
This study is limited by the following:
•  It is based on a non-randomized retrospective study of 
efﬁ  cacy and not on a prospective clinical trial. This fact 
may cause some potential bias but both designs, of course, 
have limitations that need to be remembered as the results 
are considered.
•  Our work also does not involve standard criteria for 
assessing PCO. We are assuming surgeons evaluate 
clinically signiﬁ  cant PCO in need of Nd-Yag intervention 
with reasonable consistency.
•  Estimates of the cost of complications are based on the 
one hand on a review of literature reports of the rate of 
complications, and on the other on a declaration by clini-
cians of health care consumption associated with these 
complications. Considering the variability of data in the 
literature, we have mainly chosen studies in the literature 
involving large numbers of cases. Our estimates of the 
economic value of complications are based primarily 
on the literature or available national data. Thus, while 
every effort was made to maximize accuracy, there may 
be some imprecision in our estimates.
Table 4 Budget impact on the Social Security of post-capsulotomy complications for all cataract interventions, per type of lens, accord-
ing to the method of extrapolation (€)
SA60AT AR40E XL-Stabi Total difference*
Current market share 204,045 63,598 74,198 341,842
With linear adjustment of the rate of  Yag at 5 and 6 years follow-up, then a constant rate
  Costs with current market share  18,459,158 12,053,962 21,365, 979 51,879,100 Reference
  Hypothesis 1:   All interventions with SA60AT 30,925,117 30,925,117 –20,953,983
  Hypothesis 2:   All interventions with AR40E  64,790,569 64,790,569 12,911,469
  Hypothesis 3:   All interventions with XL-Stabi  98, 436, 469 98,436,469 46,557,369
With linear adjustment from 5 to 26 years of follow-up
  Costs with current market share 19,337,675 12,721,852 22,274,013 54,333,540 Reference
  Hypothesis 1:   All interventions with SA60AT 32,396,919 32,396,919 –21,936,621
  Hypothesis 2:   All interventions with AR40E 68,380,507 68,380,507 14,046,967
  Hypothesis 3:   All interventions with XL-Stabi 102,619,925 102,619,925 48,826,385
*Difference: (Hypothesis i) – (Costs with current market share).  A negative ﬁ  gure is associated with saving.Clinical Ophthalmology 2009:3 284
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•  Also, we were not able to collect Nd-Yag complication data 
from patient charts and we had to rely on a model. In France, 
most of the ophthalmologists are not surgeons and the infor-
mation is often shared by different practitioners, some of 
whom did not participate to this survey. More importantly, 
the incidence rate of Nd-Yag adverse events is fortunately low 
and the sample size of our survey would not have allowed 
getting precise estimates. This justiﬁ  es the use of a model.
•  Following the literature review, we hypothesized that the 
Nd-Yag laser adverse events occurred within one year 
following the capsulotomy. We also hypothesized that, 
as reported in the literature, the listed (Table 1) adverse 
events were associated with the use of Nd-Yag laser, ie, 
they occurred on the top of what would have occurred in 
patients without Nd-Yag laser. This approach is accept-
able when the incidence rate of the adverse event is much 
higher than the one observed in the general population. 
For example, the probability of having glaucoma after 
Nd-Yag laser (5%, Table 1) is x10 that measured in the 
general population (0.5%).46 Lastly, discounting gives 
more importance to early (Nd-Yag related events) events 
than late events (non Nd-Yag related events), minimizing 
the economic consequences of our hypotheses.
•  Cost of blindness was limited to indirect costs and did not 
include medical costs. Also, visual impairments due to 
macular edema and retinal detachment were not taken into 
account. Consequently, blindness-related costs were slightly 
underestimated both on a national health service and societal 
perspective.
Our results demonstrate that the costs of PCO are not 
limited to the cost of carrying out Nd-Yag laser but also 
include the cost of complications, some of which may be 
persistent. Indirect costs associated with the risk of blindness 
because of Yag complications represented about 21% of the 
total costs. Our study showed that it is possible to save money 
by using more effective strategies.
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